REVIEW Lacidipine is a dihydropyridine calcium channel blocker antagonist for the treatment of hypertension. It has a high membrane partition coefficient compared to other 1,4-dihydropyridine calcium-channel antagonists and a slow washout rate from membranes. Clinically, it also exhibits an extended duration of action.
REFERENCES
[1]
Semeraro, Claudio; Micheli, Dino; Pieraccioli, Daniele; Gaviraghi, Giovanni; Borthwick, Allan David 4-Phenyl-1,4-dihydropyridinecarboxylic acid esters Ger. Offen. (1986), DE 3529997 A1 19860306.
[2]
Pieraccioli, Daniele Esterification of (carboxyethenylphenyl)dihydropyridines using amide acetals Eur. Pat. Appl. (1990), EP 370974 A2 19900530.
[3]
Sajja, Eswaraiah; Vetukuri, Venkata Naga Kali Vara Prasada Raju; Ningam, Srinivas Reddy; Vedantham, Ravindra Process for preparing lacidipine U.S. Pat. Appl. Publ. (2007), US 20070043088 A1 20070222.
[4]
Micheli D, Ratti E, Toson G, Gaviraghi G. Pharmacology of lacidipine, a vascular-selective calcium antagonist. J Cardiovasc Pharmacol. 1991;17 Suppl 4:S1-8.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.